Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Phase 3 Study to Confirm the Safety and Efficacy of T89 in Patients With Stable Angina Pectoris, With an Extended Open-label Period to Evaluate the Long-term Safety

Next Previous
Search
Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Phase 3 Study to Confirm the Safety and Efficacy of T89 in Patients With Stable Angina Pectoris, With an Extended Open-label Period to Evaluate the Long-term Safety

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T 89 (Primary) ; Nitroglycerin
  • Indications Angina pectoris; Exercise-induced angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms ORESA
  • Sponsors Tasly Pharmaceuticals, Inc.

Most Recent Events

  • 09 Apr 2025 Planned End Date changed from 1 Sep 2023 to 1 Mar 2027.
  • 09 Apr 2025 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2026.
  • 06 Mar 2023 Study design presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top